## IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No.			ation No.	:	US20070184979			
International Filing Date				:	August 9, 2007			
U.S. Serial No.				:	10/591,477			
Confirmation No.				:	1460			
Deposit Date U.S. Nat'l Phase			at'l Phase	:	September 27, 2006			
Applicant(s)				:	Thomas MAIER, et al			
Title				:	Novel sulfonylpyrroles			
<u>IN</u>	FORM	<u>IATION</u>	N DISCLOSUR	RE STATEM	ENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98			
P.O. I	missione Box 145 Indria, V	0	ntents 13-1450					
Sir:								
1.98 ฮ	This i		tion disclosure s	tatement is ma	ade in accordance with 37 C.F.R. §§ 1.56, 1.97 and			
<u> Timir</u>	ng and F	<u>ees</u>						
	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:							
		withir		f the filing dat	e of a national application other than a CPA under §			
		within three months of the actual filing date of the national phase of a PCT application; OR						
		before the mailing of a first substantive office action (including after filing of an RCE).						
$\boxtimes$		Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods pecified in 37 C.F.R. § 1.97(b), but before the mailing date of:						
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and is accompanied by:						
			the statement	as specified in	a 37 C.F.R. § 1.97(e) set out below; OR			

		$\boxtimes$	a credit card payment covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).			
	Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:					
		a final action under 37 C.F.R. § 1.113;				
		termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);				
		OR a notice of allowance under 37 C.F.R. § 1.311;				
	AND is filed on or before payment of the issue fee; AND is accompanied by:					
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 0 under 37 C.F.R. § 1.17(p).			
Statements Under 37 C.F.R. 1.97(e)						
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or			
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.			
Cited I	Material	<u>ls</u>				
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 12 ancestor application Serial No, on Form 892 by the Examiner and/or Form 14 by the applicant; see 37 C.F.R. § 1.98(d).				
		Copies of materials listed were cited in an international search report dated				
	$\boxtimes$	Not rec	quired by 37 CFR § 1.98.			
	$\boxtimes$	Copies	of the materials listed are attached (except for the foregoing).			

Non-English Language References

	X	An English-language search report or equivalent paper from a foreign patent office provided indicating the relevance of the cited reference(s) in said search report.				
		A foreign-language search report from a foreign patent office is provided, and pertine parts are translated substantively below:				
		<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> </ul>				
		<ul> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the invention</li> <li>E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date</li> <li>D = cited in the application</li> <li>L = cited for another reason</li> <li>&amp; = publication of member of same patent family</li> </ul>				
		Translation of other relevant information on foreign search report:				
Other ]	<u>Informa</u>	<u>tion</u>				
Payme	ent of Fees Due (If Any):  A check for \$ covering the fee identified above is attached.  Fees are to be charged to a credit card.  Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.					

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402.

Respectfully submitted,

/Csaba Henter/
Csaba Henter, Reg. No. 50,908
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: VOSS-0031

Date: October 14, 2009